Diabetes and obesity drug developer Novo Nordisk on Thursday significantly raised its full-year operating profit and sales expectations on the back of strong demand for its highly popular Wegovy obesity drug.

The benefits of obesity drugs such as Novo Nordisk’s Wegovy on healthcare systems in countries such as the United States are so significant that the expected entry of rival drugs will not hurt its margins, CEO Lars Jorgensen told Reuters on Tuesday.